Literature DB >> 25862890

Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer.

Sumiya Ishigami1, Takaaki Arigami2, Hiroshi Okumura2, Yasuto Uchikado2, Yoshiaki Kita2, Hiroshi Kurahara2, Kosei Maemura2, Yuko Kijima2, Yuka Ishihara2, Ken Sasaki2, Yoshikazu Uenosono2, Shoji Natsugoe2.   

Abstract

Human leukocyte antigen (HLA)-E and HLA-F are classified as non-classical HLA class Ib antigens. Ectopic HLA-E and HLA-F expression was recently detected in cancer cells; however, the clinical implication of their expression remains unknown. A total of 209 patients with gastric cancer were enrolled in this study. Immunohistochemistry was used to evaluate the expression of HLA-E and HLA-F in gastric cancer specimens. HLA-E and HLA-F expression were seen in the cell membrane. HLA-E and HLA-F expression significantly correlated with depth of invasion, nodal involvement, lymphatic invasion, and venous invasion. No significant correlation between HLA-E and HLA-F expression was found (p<0.05, r=0.24). The five-year survival rate of the HLA-E-positive group and HLA-F-positive group were significantly poorer than that of their respective negative groups. Combination of HLA-E and HLA-F made the p-value smaller than single analysis (p<0.009). This is the first report detailing a clinical implication of HLA-E and HLA-F expression simultaneously in gastric cancer. We identified that the HLA-E and HLA-F in gastric cancer independently affected clinical factors, including postoperative outcome. For HLA-E- or HLA-F-positive gastric cancer, we should settle on a treatment strategy that reinforces the host immune response. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Gastric cancer; HLA-E; HLA-F; immuno suppression; postoperative outcome

Mesh:

Substances:

Year:  2015        PMID: 25862890

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

1.  HLA-Fatal attraction.

Authors:  Frédéric Vély; Rachel Golub; Eric Vivier
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

2.  HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

Authors:  Zijun Zhen; Kaibin Yang; Litong Ye; Zhiyao You; Rirong Chen; Ying Liu; Youjian He
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

3.  HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation.

Authors:  Tomas Hrbac; Alena Kopkova; Frantisek Siegl; Marek Vecera; Michaela Ruckova; Tomas Kazda; Radim Jancalek; Michal Hendrych; Marketa Hermanova; Vaclav Vybihal; Pavel Fadrus; Martin Smrcka; Filip Sokol; Vaclav Kubes; Radim Lipina; Ondrej Slaby; Leos Kren; Jiri Sana
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

4.  Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer.

Authors:  Takeshi Morinaga; Masaaki Iwatsuki; Kohei Yamashita; Chihiro Matsumoto; Kazuto Harada; Junji Kurashige; Shiro Iwagami; Yoshifumi Baba; Naoya Yoshida; Yoshihiro Komohara; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2022-04-12       Impact factor: 5.344

5.  Dynamic Alteration in HLA-E Expression and Soluble HLA-E via Interaction with Natural Killer Cells in Gastric Cancer.

Authors:  Takeshi Morinaga; Masaaki Iwatsuki; Kohei Yamashita; Noriko Yasuda-Yoshihara; Taishi Yamane; Chihiro Matsumoto; Kazuto Harada; Kojiro Eto; Junji Kurashige; Takatsugu Ishimoto; Yoshifumi Baba; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2022-09-23       Impact factor: 4.339

6.  Epigenome-Wide DNA Methylation Profiling of Normal Mucosa Reveals HLA-F Hypermethylation as a Biomarker Candidate for Serrated Polyposis Syndrome.

Authors:  Gerhard Jung; Eva Hernández-Illán; Juan J Lozano; Julia Sidorova; Jenifer Muñoz; Yasuyuki Okada; Enrique Quintero; Goretti Hernandez; Rodrigo Jover; Sabela Carballal; Miriam Cuatrecasas; Lorena Moreno; Mireia Diaz; Teresa Ocaña; Ariadna Sánchez; Liseth Rivero; Oswaldo Ortiz; Joan Llach; Antoni Castells; Maria Pellisé; Ajay Goel; Eduard Batlle; Francesc Balaguer
Journal:  J Mol Diagn       Date:  2022-04-18       Impact factor: 5.341

7.  High HLA-F Expression Is a Poor Prognosis Factor in Patients with Nasopharyngeal Carcinoma.

Authors:  Bo Wu; Haihua Yang; Shenpeng Ying; Hongsheng Lu; Wei Wang; Jiaming Lv; Huacai Xiong; Wei Hu
Journal:  Anal Cell Pathol (Amst)       Date:  2018-10-30       Impact factor: 2.916

8.  Single-cell RNA-seq variant analysis for exploration of genetic heterogeneity in cancer.

Authors:  Erik Fasterius; Mathias Uhlén; Cristina Al-Khalili Szigyarto
Journal:  Sci Rep       Date:  2019-07-02       Impact factor: 4.379

Review 9.  HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation.

Authors:  Burcu Duygu; Timo I Olieslagers; Mathijs Groeneweg; Christina E M Voorter; Lotte Wieten
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

10.  The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.

Authors:  Mehrdad Talebian Yazdi; Sander van Riet; Annemarie van Schadewijk; Marta Fiocco; Thorbald van Hall; Christian Taube; Pieter S Hiemstra; Sjoerd H van der Burg
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.